Kura Oncology, Inc. Ratios

Ratios Dec2010 Dec2012 Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin 1,187.43%549.16%486.83%450.18%59,318.78%9,853.52%-319.15%
EBIT Margin 1,087.43%449.16%386.83%350.18%61,076.42%10,703.94%-358.55%
EBITDA Margin 1,087.43%449.16%386.83%350.18%49,373.91%4,764.47%3,993.81%6,240.10%10,806.55%15,555.36%31,956.76%62,044.98%9,417.04%-319.11%
Operating Margin 1,087.43%449.16%386.83%350.18%61,076.42%10,703.94%-358.55%
Net Margin 1,187.43%549.16%486.83%450.18%59,318.78%9,853.52%-322.89%
FCF Margin 1,020.36%490.91%395.34%233.70%39,106.52%4,393.24%3,202.82%5,015.98%9,441.38%12,456.92%25,530.92%48,335.37%8,069.21%248.40%
Efficiency
Invested Capital 416.25M
Leverage & Solvency
Interest Coverage Ratio -10.87-4.49-3.87-3.50-610.76-107.04-119.33
Debt to Equity 0.02
Debt Ratio 0.01
Equity Ratio 0.54
Times Interest Earned -10.87-4.49-3.87-3.50-610.76-107.04-119.33
Valuation
Enterprise Value 179.51M126.07M462.30M534.04M623.08M1,852.09M931.78M830.19M1,068.03M-50.07M
Market Capitalization 830.19M1,068.03M677.32M
Return Ratios
Return on Sales 11.87%5.49%4.87%4.50%593.19%98.54%-3.23%